Literature DB >> 10602701

Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters.

P Buchwald1, N Bodor.   

Abstract

An attempt to quantitatively describe human blood in vitro hydrolysis data for more than 80 compounds belonging to seven different noncongener series of ester-containing drugs is presented. A parameter not yet explored in pharmaceutical studies, the inaccessible solid angle Omega(h), calculated around different atoms was used as a measure of steric hindrance, and the steric hindrance around the carbonyl sp(2) oxygen (Omega(h)(O=)) proved the most relevant parameter. The obtained final equation, log t(1/2) = -3.805 + 0.172Omega(h)(O=) - 10.146q(C=) + 0.112QLogP, also includes the AM1-calculated charge on the carbonyl carbon (q(C=)) and a calculated log octanol-water partition coefficient (QLogP) as parameters and accounts for 80% of the variability in the log half-lives of 67 compounds. A number of structures are still mispredicted, but the equation agrees very well with a recently proposed mechanism for hydrolysis by carboxylesterases. The model, with a predictive power tested here on three unrelated structures, should be useful in estimating approximate rates of hydrolysis for prodrug or soft drug candidates ahead of their synthesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602701     DOI: 10.1021/jm990145k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Receptor binding studies of soft anticholinergic agents.

Authors:  F Huang; P Buchwald; C E Browne; H H Farag; W M Wu; F Ji; G Hochhaus; N Bodor
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

3.  Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.

Authors:  Federica Vacondio; Claudia Silva; Alessio Lodola; Caterina Carmi; Silvia Rivara; Andrea Duranti; Andrea Tontini; Silvano Sanchini; Jason R Clapper; Daniele Piomelli; Giorgio Tarzia; Marco Mor
Journal:  Eur J Med Chem       Date:  2011-07-21       Impact factor: 6.514

Review 4.  Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.

Authors:  Collen M Masimirembwa; Ulf Bredberg; Tommy B Andersson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs.

Authors:  Chaoyi Deng; Jin Liu; Wensheng Zhang
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

6.  Polymeric persulfide prodrugs: Mitigating oxidative stress through controlled delivery of reactive sulfur species.

Authors:  Kearsley M Dillon; Ryan J Carrazzone; Yin Wang; Chadwick R Powell; John B Matson
Journal:  ACS Macro Lett       Date:  2020-04-07       Impact factor: 6.903

7.  A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.

Authors:  Hui Ouyang; Fuxing Tang; Teruna J Siahaan; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

8.  Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action.

Authors:  S Shaukat Husain; Ervin Pejo; Rile Ge; Douglas E Raines
Journal:  Anesthesiology       Date:  2012-11       Impact factor: 7.892

9.  Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats.

Authors:  Federica Vacondio; Michele Bassi; Claudia Silva; Riccardo Castelli; Caterina Carmi; Laura Scalvini; Alessio Lodola; Valentina Vivo; Lisa Flammini; Elisabetta Barocelli; Marco Mor; Silvia Rivara
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.